Orexo appoints Henrik Juuel as new CFO
Uppsala, Sweden – July 15, 2013 - Orexo AB today announced the appointment of Henrik Juuel as the new Executive Vice President and CFO. Henrik Juuel will be a member of the company’s executive management team, succeeding Carl-Johan Blomberg, who will leave Orexo as CFO of the company after successful two year tenure. Carl-Johan will continue to support Orexo and Henrik in a transition period.
“On behalf of Orexo, I would like to thank Carl-Johan Blomberg for his engagement and involvement in transforming Orexo in to a commercially focused company over the past years. He has taken important part in ensuring that Orexo is financially strong and well prepared to support the launch of Zubsolv” says Nikolaj Sørensen, President and CEO of Orexo AB.
Orexo is entering a new phase with increasing effort towards commercialization of the company’s lead product Zubsolv, approved by the FDA earlier this month for the US market. Henrik Juuel brings extensive relevant experience from senior international management positions within the life science industry, including positions as CFO for NNE Pharmaplan and GN Resound.
“Henrik Juuel has an impressive career track, having worked in multiple and increasingly senior positions within different finance functions in the life science industry. His experience from financial management of international commercial operations will be important for the continued success of Orexo AB, as our company continues expanding” says Nikolaj Sørensen, President and CEO of Orexo AB.
Henrik Juuel commented “I am honored to be appointed CFO of Orexo, and I look forward to closely working with Nikolaj Sørensen to complete the transformation of Orexo to a commercial company with growing international sales and strong partnerships. I am excited about the company’s future opportunities and be a part of the leadership of Orexo.”
For further information, please contact:
Nikolaj Sørensen, President and CEO
Tel: +46 70-350 78 88, E-mail: [email protected]
Orexo is an emerging specialty pharma company with commercial operations in the United States and R&D in Sweden developing improved treatments using proprietary drug delivery technology. Orexo’s expertise is within the area of reformulation technologies and especially sublingual formulations. The company has a portfolio of revenue-generating US and EU approved products currently marketed under license and a pipeline of several reformulations of approved compounds for areas of unmet medical need. Orexo also has collaboration projects with several international pharmaceutical companies. Orexo, with its headquarters in Sweden, is listed on NASDAQ-OMX. The largest shareholders are Novo A/S and HealthCap.
For more information about Orexo please visit www.orexo.com.
Orexo is required under the Financial Instruments Trading Act to make the information in this press release public. The information was submitted for publication at 08:55 am CET on July 15, 2013.